Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03587844 · ClinicalTrials.gov registry record · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
A Phase 2 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 8
- Study locations
NCT03587844: Recruiting Phase 2 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03587844 is a Phase 2 study of Mycosis Fungoides and Sezary Syndrome that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 58 participants, below the 161-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (64% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03587844, a Phase 2 study of Mycosis Fungoides and Sezary Syndrome, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
Primary Outcome
measure best overall response during treatment by the global response score, which incorporates the mSWAT, as well as CT scan for patients with baseline nodal/visceral involvement and flow cytometry for patients with baseline positive peripheral flow cytometry
Conditions Studied
Interventions
- DRUG brentuximab vedotin
Study Locations (8)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
California
- Stanford University Medical Center - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT03587844 shows while recruiting
NCT03587844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 161-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (64% lower).
The record links to 3 conditions, with Mycosis Fungoides appearing as the primary indexed condition, and to 1 intervention - of which brentuximab vedotin is the first listed.
NCT03587844 lists 8 locations in 3 states (New York, New Jersey, California).
Frequently Asked Questions
What is clinical trial NCT03587844 about?
NCT03587844 is a clinical study titled "Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients". The purpose of this study is to test any good and bad effects of the study drug called brentuximab vedotin at a lower dose than is FDA-approved.
What is the current status of trial NCT03587844?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2018-07-03. Estimated completion is 2026-07.
What conditions does trial NCT03587844 study?
This clinical trial studies the following conditions: Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis.
What interventions are being tested in trial NCT03587844?
The interventions under investigation include: brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT03587844?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03587844 being conducted?
This trial has 8 study locations across California, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03587844's enrollment target sits among peer trials
58 9th of 19 higher than 11 of 19 other Mycosis Fungoides trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mycosis Fungoides trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
RECRUITING · Phase 2
-
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
- NCT04373473 · 58 participants · Phase 2
Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI